Clinical Trials Browser

Phase 1/2 × Completed × ibritumomab tiuxetan × Clear all

NCT00562978 2021-06-18

Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00438880 2016-02-04

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

Phase 1/2 Completed

38 enrolled 8 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01538472 2014-09-11

Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma

Phase 1/2 Completed

40 enrolled 6 charts

Lymphoid

Lymphoma

NCT00064246 2013-01-25

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

Phase 1/2 Completed

28 enrolled

Lymphoid

Burkitt Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse